CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. reported second-quarter 2026 results as a clinical-stage biopharmaceutical company with no product revenue and an accumulated deficit of $192.0 million. For the quarter ended June 30, 2026, operating expenses fell to $4.0 million from $6.6 million a year earlier, reflecting lower research and development and general and administrative spending.
The company recorded a Q2 2026 net loss of $7.7 million compared with $6.0 million in Q2 2025, driven partly by a $3.6 million noncash loss from changes in fair value of financial instruments. For the first six months of 2026, net loss was $2.7 million versus $11.0 million in the prior-year period, largely due to favorable fair value movements earlier in the year.
Cash and cash equivalents increased to $18.6 million at June 30, 2026 from $11.5 million at year-end, primarily from a June PIPE financing and at-the-market sales providing $15.0 million gross proceeds. Total liabilities decreased to $14.0 million, while stockholders’ equity improved from a deficit of $(6.6) million to positive equity of $5.5 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital, given projected operating needs and a $9.2 million fair-valued promissory note and $1.3 million warrant liability on the balance sheet.
CalciMedica, Inc. reported second quarter 2026 results and outlined pipeline and financing updates. A private placement of up to approximately $49 million, including approximately $15 million upfront, is intended to advance its pulmonary hypertension strategy around Auxora and oral candidate CM5480. The company plans a Phase 1b proof‑of‑concept trial of Auxora in pulmonary arterial hypertension with data anticipated in mid‑2027, and expects an IND submission for CM5480 in mid‑2027. In acute pancreatitis, the FDA aligned on the Phase 2b trial design with a primary endpoint focused on reducing new‑onset severe respiratory failure, though trial initiation depends on additional financing. Cash and cash equivalents were $18.6 million as of June 30, 2026, and the company expects its cash to fund operations into the second half of 2027. For the quarter, net loss was $7.7 million (or $0.45 per share), compared with a net loss of $6.0 million (or $0.40 per share) a year earlier, while operating expenses declined due to lower R&D and G&A spending.
CalciMedica, Inc. has filed a resale registration covering up to 56,020,287 shares of common stock for selling stockholders. These include 14,938,370 issued shares, 3,735,059 shares issuable upon exercise of pre-funded warrants, 18,673,429 shares issuable upon exercise of Series A warrants, and 18,673,429 shares issuable upon exercise of Series B warrants, all tied to a June 23, 2026 private placement of 18,673,429 units.
The company is not selling shares itself and will receive no proceeds from stockholder resales, but would receive cash upon warrant exercises at $0.0001 per pre-funded warrant share, $0.8033 per Series A Warrant share (or $0.8032 per related pre-funded warrant), and $1.00 per Series B Warrant share (or $0.9999 per related pre-funded warrant). Shares outstanding were 30,736,401 as of July 9, 2026; this is a baseline figure, not the amount being offered.
Warrants and pre-funded warrants are subject to beneficial ownership limits up to 19.99%. CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibitors, including Auxora and CM5480, and qualifies as a smaller reporting company on Nasdaq under the symbol CALC.
CalciMedica, Inc. is asking stockholders to vote at the virtual 2026 annual meeting on August 19, 2026. Holders of 30,736,401 shares of common stock outstanding as of July 21, 2026 are entitled to one vote per share.
Key items include electing two Class III directors, ratifying Baker Tilly US, LLP as auditor for 2026, amending the Amended 2023 Equity Incentive Plan to add 7,500,000 shares (for a total of 12,333,690) and broadening the evergreen calculation, advisory votes on executive pay and its frequency, and authority to implement a reverse stock split between 1-for-2 and 1-for-10 with a proportionate reduction in authorized common shares, at the Board’s discretion if approved. Stockholders are also asked to approve, for Nasdaq Listing Rule 5635(d) and 5635(c) purposes, issuances under a June 23, 2026 Purchase Agreement, including Series A and B Warrants for up to 18,673,429 shares each and separate director and officer tranches of 1,680,565 shares each. The Board recommends voting FOR all proposals and a one-year say-on-pay frequency.
CalciMedica, Inc. has a new institutional holder disclosure on Schedule 13G. CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 1,556,081 shares of CalciMedica common stock, representing 5.1% of the class, with shared voting and dispositive power over these shares.
The ownership percentage is calculated using 15,798,031 shares outstanding as of May 6, 2026, as reported in a recent quarterly report, plus 14,938,370 shares issued in a subsequent private placement. Heights Capital Management acts as investment manager to CVI Investments and may be deemed a beneficial owner of these shares, while each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest.
CalciMedica, Inc. is holding a virtual 2026 annual stockholder meeting on August 19, 2026 to vote on eight proposals, including electing two Class III directors and ratifying Baker Tilly US, LLP as independent auditor for the year ending December 31, 2026.
Stockholders will consider amending the 2023 Equity Incentive Plan to add more shares and adjust its Evergreen Mechanism to include shares issuable from convertible preferred stock and pre-funded warrants, plus advisory votes on executive compensation and on how often future say-on-pay votes occur.
The agenda also includes a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-10 with a proportionate authorized share reduction, and approvals under Nasdaq Listing Rules 5635(d) and 5635(c) for issuing Series A and Series B warrants covering up to 18,673,429 shares each, including 1,680,565 shares under each series for directors and officers, along with the shares issuable upon exercise.
As context, 30,736,401 shares of common stock were outstanding and 4,682,290 options were outstanding at a weighted-average exercise price of $2.36 as of July 9, 2026; this is a baseline figure, not the amount being offered.
ALAFI CAPITAL CO LLC, a greater-than-10% owner of CalciMedica, Inc., reported beneficial ownership of 5,112,345 shares of Common Stock. It also holds Common Share Warrants exercisable for 130,651 shares of Common Stock at an exercise price of $7.15 per share. The warrants were issued on July 22, 2025 and expire on the earlier of 5:00 p.m. New York City time on December 31, 2026 or 30 days following the company’s public disclosure of topline results from its planned Phase 2 clinical trial in patients with acute kidney injury.
Alafi Capital Company LLC and Christopher D. Alafi report beneficial ownership of 5,242,996 shares of CalciMedica, Inc. common stock, representing 17.1% of the class. This includes 5,112,345 shares held directly and 130,651 shares underlying a warrant exercisable at $7.15 per share. Shares outstanding were 30,736,401 as of June 25, 2026; this is a baseline figure, not the amount acquired. Alafi Capital purchased 3,529,192 units in a June 25, 2026 private placement at $0.8033 per unit for approximately $2.8 million, receiving 3,529,192 shares plus rights to Series A and Series B warrants, each to purchase 3,529,192 additional shares upon stockholder approval. Various pre-funded and series warrants feature low exercise prices, cashless exercise provisions, and beneficial ownership limitations up to 19.99%.